Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Depression
Interventions
Escitalopram, Interpersonal Psychotherapy, Clinical Monitoring
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
sapacitabine and decitabine (Part 1 - completed), sapacitabine and venetoclax (Part 2 - recruiting)
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • Houston, Texas
Completed Not applicable Interventional Results available

Post-Operative Delirium in Elderly Surgical Patients

NCT00590707
Conditions
Hip Fractures, Delirium
Interventions
Deeper sedation, Moderate sedation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Illnesses
Interventions
Physical activity plus positive affect, Physical activity plus education
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 110 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Duke Conte Center for the Neuroscience of Depression in Late Life

NCT00576875
Conditions
Major Depression
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Results available

Yoga in Older Cardiac Patients

NCT06235658
Conditions
Cardiovascular Diseases in Old Age
Interventions
Gentle Yoga
Behavioral
Lead sponsor
Geunyeong Cha
Other
Eligibility
65 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 2 Interventional Results available

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378
Conditions
Post-operative Cognitive Decline, Post-operative Delirium
Interventions
Aspart insulin, Normal saline, Intranasal mucosal atomizer device
Drug · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Accidental Falls, Aging
Interventions
Personalized tDCS, Active-Sham
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
60 Years to 100 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Roslindale, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Preventative Delirium Protocol in Elderly Patients

NCT03541408
Conditions
Delirium
Interventions
Control, Preventative Delirium Protocol
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
65 Years to 89 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Fall Prevention
Interventions
Resistance training
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
AML, Adult
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alcohol Consumption, Drug-Food Interaction
Interventions
Online alcohol educational class
Behavioral
Lead sponsor
Arlene Fink Associates
Industry
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pacific Palisades, California
Conditions
Healthy Volunteers
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Conditions
Vaccination
Interventions
Informational Animation Video, Personal Narrative Video
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
50 Years and older
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943488
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Seattle, Washington
Conditions
Influenza
Interventions
GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more
Conditions
Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Parathyroid Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Thyroid Cancer, Recurrent Verrucous Carcinoma of the Larynx, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Larynx, Stage IIIB Non-small Cell Lung Cancer, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Basal Cell Carcinoma of the Lip, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Follicular Thyroid Cancer, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Lymphoepithelioma of the Oropharynx, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Papillary Thyroid Cancer, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Basal Cell Carcinoma of the Lip, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Follicular Thyroid Cancer, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Lymphoepithelioma of the Oropharynx, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Papillary Thyroid Cancer, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Basal Cell Carcinoma of the Lip, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Follicular Thyroid Cancer, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Lymphoepithelioma of the Oropharynx, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Papillary Thyroid Cancer, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Thryoid Gland Nonmedullary Carcinoma, Thyroid Gland Medullary Carcinoma, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
gefitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Antonio, Texas
Not listed Not applicable Interventional Accepts healthy volunteers

Cardiac and Vascular Responses to Creatine Supplementation in Elderly Men

NCT05329480
Conditions
Cardiac Function and Hemodynamics
Interventions
Creatine Monohydrate, Maltodextrin
Dietary Supplement
Lead sponsor
Radford University
Other
Eligibility
55 Years to 80 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Localized Head and Neck Carcinoma
Interventions
Best Practice, Electronic Health Record Review, Health Communication, Interview, Office Visit, Practical Geriatric Assessment, Questionnaire Administration, Referral, Supportive Care
Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Alzheimer Disease
Interventions
Educational Materials
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
50 Years and older
Enrollment
11,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Hip Fracture, Depression
Interventions
Enhanced acute medical rehabilitation, Treatment as usual
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri